Cenobamate not checked

SK Life Science, Inc. · YKP3089 · YKP3089C045

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
4 active
17 in total · 4 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“The 100 mg/ day Treatment Period includes a 6-week Titration Phase and a 26-week Maintenance Phase. During the Titration Phase subjects will be treated with cenobamate 12.5 mg/day for two weeks, 25 mg/day for two weeks and 50 mg/day for two weeks. Subjects tolerating cenobamate at the end of the Titration Phase will continue treatment with 100 mg/day in the Maintenance Phase for 26 weeks. If the…”In the company’s words, NCT06453213 on ClinicalTrials.gov
Tested for
Focal Onset Seizure, Epilepsy, Generalized, Partial Epilepsy, Epilepsies, Partial
Main trialPhase 4
“Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagnosed or recurrent POS/focal onset epilepsy.”In the company’s words, NCT06453213 on ClinicalTrials.gov
Other names
YKP3089 · YKP3089C045 · Xcopri

Other drugs for Focal Onset Seizure

All 20 drugs for Focal Onset Seizure

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials17

TrialPhaseCompletesWhat it tests
Phase 4Active, not recruiting 26 May 2027 Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
Phase 3Recruiting 31 Jan 2027 ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.
Phase 3Recruiting 30 Mar 2028 A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds
Phase 2Recruiting 31 Jan 2027 Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures
Phase 3Completed 31 Mar 2021 Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Phase 3Completed 16 Feb 2024 Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS
Phase 3Completed 26 May 2025 Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
Phase 3Completed 10 Jun 2026 Cenobamate Open-Label Extension Study for YKP3089C025
Phase 3Completed 2 Oct 2026 Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Phase 2Completed Jun 2013 Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
Phase 2Completed 5 Apr 2021 A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Phase 1Completed 3 Jul 2017 Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions
Phase 1Completed 18 Nov 2017 A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users
Phase 1Completed 17 May 2021 Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet
Phase 1Completed 15 Nov 2022 Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment
Phase 1Completed 28 Jan 2023 A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally
Phase 1Completed 6 Nov 2025 Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Cenobamate

Following is part of Solo: you see every change to Cenobamate the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in